 Nikita Pozdeyev
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 11 | 2024 | 264 | 2.720 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2020 | 34 | 1.550 |
Why?
| | Retina | 12 | 2012 | 263 | 1.040 |
Why?
| | Thyroid Nodule | 1 | 2024 | 39 | 0.880 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2021 | 48 | 0.870 |
Why?
| | Adrenocortical Carcinoma | 2 | 2021 | 47 | 0.860 |
Why?
| | Thyroxine | 1 | 2023 | 56 | 0.840 |
Why?
| | Hypothyroidism | 1 | 2023 | 64 | 0.830 |
Why?
| | Melatonin | 7 | 2009 | 106 | 0.800 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2023 | 192 | 0.770 |
Why?
| | Circadian Rhythm | 8 | 2011 | 356 | 0.690 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2020 | 29 | 0.680 |
Why?
| | Splenectomy | 1 | 2020 | 52 | 0.670 |
Why?
| | Dopamine | 9 | 2018 | 236 | 0.660 |
Why?
| | Bacterial Vaccines | 1 | 2020 | 61 | 0.660 |
Why?
| | Biomarkers, Tumor | 4 | 2021 | 1040 | 0.650 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 222 | 0.620 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2021 | 636 | 0.550 |
Why?
| | Pharmacogenomic Testing | 1 | 2016 | 53 | 0.520 |
Why?
| | Guideline Adherence | 1 | 2020 | 490 | 0.510 |
Why?
| | Databases, Genetic | 1 | 2016 | 206 | 0.490 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1879 | 0.490 |
Why?
| | NF-kappa B | 2 | 2015 | 641 | 0.470 |
Why?
| | Mutation | 9 | 2021 | 3346 | 0.460 |
Why?
| | Sepsis | 1 | 2020 | 509 | 0.450 |
Why?
| | Photoreceptor Cells, Vertebrate | 3 | 2012 | 25 | 0.440 |
Why?
| | Data Collection | 1 | 2016 | 620 | 0.440 |
Why?
| | Genetic Variation | 1 | 2018 | 870 | 0.420 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1395 | 0.400 |
Why?
| | Genomics | 4 | 2024 | 635 | 0.400 |
Why?
| | Photoreceptor Cells | 3 | 2008 | 12 | 0.390 |
Why?
| | Signal Transduction | 4 | 2018 | 4515 | 0.340 |
Why?
| | Eye Proteins | 3 | 2008 | 70 | 0.330 |
Why?
| | Adenocarcinoma, Follicular | 2 | 2019 | 34 | 0.320 |
Why?
| | Cell Line, Tumor | 8 | 2021 | 2710 | 0.310 |
Why?
| | GTP-Binding Protein Regulators | 1 | 2008 | 2 | 0.310 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 179 | 0.300 |
Why?
| | Arylalkylamine N-Acetyltransferase | 2 | 2006 | 2 | 0.290 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 13 | 0.270 |
Why?
| | Phosphoproteins | 1 | 2008 | 298 | 0.260 |
Why?
| | Humans | 24 | 2024 | 114698 | 0.230 |
Why?
| | MAP Kinase Signaling System | 2 | 2023 | 276 | 0.230 |
Why?
| | Kynuramine | 1 | 2003 | 1 | 0.230 |
Why?
| | Biological Clocks | 4 | 2008 | 38 | 0.220 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1167 | 0.210 |
Why?
| | Computers | 1 | 2023 | 60 | 0.210 |
Why?
| | Levodopa | 2 | 2018 | 23 | 0.210 |
Why?
| | Dopamine Agents | 2 | 2018 | 14 | 0.210 |
Why?
| | Neoplasms | 1 | 2016 | 2097 | 0.210 |
Why?
| | Thyrotropin | 1 | 2023 | 99 | 0.210 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 6 | 2011 | 17 | 0.200 |
Why?
| | Data Warehousing | 1 | 2022 | 5 | 0.200 |
Why?
| | Cloud Computing | 1 | 2022 | 6 | 0.200 |
Why?
| | Light | 4 | 2009 | 337 | 0.200 |
Why?
| | Retinal Rod Photoreceptor Cells | 3 | 2018 | 11 | 0.190 |
Why?
| | Immunohistochemistry | 5 | 2020 | 1629 | 0.190 |
Why?
| | Receptor, Melatonin, MT1 | 2 | 2011 | 5 | 0.180 |
Why?
| | Pheochromocytoma | 1 | 2021 | 54 | 0.180 |
Why?
| | Ultrasonography | 1 | 2024 | 634 | 0.180 |
Why?
| | MutS Homolog 2 Protein | 1 | 2020 | 12 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 146 | 0.180 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2020 | 13 | 0.180 |
Why?
| | Paraganglioma | 1 | 2021 | 47 | 0.180 |
Why?
| | Night Blindness | 2 | 2012 | 6 | 0.180 |
Why?
| | Precision Medicine | 1 | 2024 | 337 | 0.170 |
Why?
| | Calcitonin | 1 | 2020 | 23 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1141 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 164 | 0.170 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 85 | 0.170 |
Why?
| | Trans-Activators | 2 | 2021 | 367 | 0.170 |
Why?
| | Haemophilus influenzae type b | 1 | 2020 | 10 | 0.170 |
Why?
| | Receptors, Virus | 1 | 2020 | 75 | 0.170 |
Why?
| | Neisseria meningitidis | 1 | 2020 | 18 | 0.170 |
Why?
| | Organizational Case Studies | 1 | 2020 | 69 | 0.170 |
Why?
| | Myopia | 2 | 2012 | 36 | 0.170 |
Why?
| | Animals | 23 | 2021 | 31708 | 0.170 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.160 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1693 | 0.160 |
Why?
| | Postoperative Complications | 2 | 2023 | 2128 | 0.160 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 157 | 0.160 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 372 | 0.160 |
Why?
| | Crk-Associated Substrate Protein | 1 | 2018 | 5 | 0.160 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2018 | 27 | 0.160 |
Why?
| | Immune System | 1 | 2020 | 172 | 0.160 |
Why?
| | Leukocytes | 1 | 2020 | 276 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2018 | 47 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 858 | 0.160 |
Why?
| | Streptococcus pneumoniae | 1 | 2020 | 133 | 0.160 |
Why?
| | src-Family Kinases | 1 | 2018 | 88 | 0.150 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 33 | 0.150 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 37 | 0.150 |
Why?
| | Adrenal Cortex | 1 | 2018 | 32 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 228 | 0.150 |
Why?
| | Rod Opsins | 2 | 2009 | 7 | 0.150 |
Why?
| | Oncogenes | 1 | 2018 | 103 | 0.140 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 30 | 0.140 |
Why?
| | Neoplasm Grading | 1 | 2018 | 242 | 0.140 |
Why?
| | Dark Adaptation | 3 | 2018 | 13 | 0.140 |
Why?
| | Telomerase | 1 | 2019 | 206 | 0.140 |
Why?
| | Gene Frequency | 1 | 2018 | 477 | 0.140 |
Why?
| | Mice | 13 | 2021 | 14871 | 0.140 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1518 | 0.130 |
Why?
| | Amino Acids | 1 | 2000 | 448 | 0.130 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2018 | 160 | 0.130 |
Why?
| | Photic Stimulation | 2 | 2008 | 203 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1121 | 0.130 |
Why?
| | Electroretinography | 5 | 2018 | 40 | 0.130 |
Why?
| | Disease Progression | 2 | 2020 | 2380 | 0.130 |
Why?
| | Diabetic Retinopathy | 1 | 2018 | 149 | 0.130 |
Why?
| | Disease Management | 1 | 2020 | 560 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 282 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2021 | 2187 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 932 | 0.130 |
Why?
| | Caspase 7 | 1 | 2015 | 20 | 0.130 |
Why?
| | Tyrosine 3-Monooxygenase | 3 | 2018 | 68 | 0.130 |
Why?
| | Mice, Knockout | 6 | 2018 | 2570 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2016 | 106 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 395 | 0.130 |
Why?
| | Bortezomib | 1 | 2015 | 41 | 0.130 |
Why?
| | User-Computer Interface | 1 | 2016 | 140 | 0.130 |
Why?
| | Thyroidectomy | 1 | 2015 | 53 | 0.130 |
Why?
| | Inhibitory Concentration 50 | 1 | 2015 | 74 | 0.130 |
Why?
| | Hypocalcemia | 1 | 2015 | 31 | 0.120 |
Why?
| | Genetic Testing | 1 | 2018 | 381 | 0.120 |
Why?
| | Radiation, Ionizing | 1 | 2015 | 72 | 0.120 |
Why?
| | Pharmacogenetics | 1 | 2016 | 149 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 445 | 0.120 |
Why?
| | Taxoids | 1 | 2015 | 93 | 0.120 |
Why?
| | Caspase 3 | 1 | 2015 | 235 | 0.120 |
Why?
| | Computational Biology | 1 | 2018 | 530 | 0.110 |
Why?
| | Cell Death | 1 | 2015 | 323 | 0.110 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1131 | 0.110 |
Why?
| | Macrophages | 1 | 2020 | 1263 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1355 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2014 | 237 | 0.110 |
Why?
| | Phosphorylation | 2 | 2008 | 1569 | 0.110 |
Why?
| | Models, Biological | 1 | 2020 | 1621 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2012 | 225 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 347 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 228 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 281 | 0.100 |
Why?
| | Mice, Nude | 3 | 2021 | 630 | 0.100 |
Why?
| | Retinal Bipolar Cells | 1 | 2012 | 6 | 0.100 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2320 | 0.100 |
Why?
| | Calcium | 2 | 2015 | 1108 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 4694 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 785 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 32 | 0.090 |
Why?
| | Algorithms | 1 | 2018 | 1470 | 0.090 |
Why?
| | Obesity | 1 | 2023 | 2508 | 0.090 |
Why?
| | Dopamine beta-Hydroxylase | 1 | 2010 | 12 | 0.090 |
Why?
| | Disulfiram | 1 | 2010 | 13 | 0.090 |
Why?
| | Alcohol Deterrents | 1 | 2010 | 17 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3329 | 0.090 |
Why?
| | Female | 7 | 2021 | 59520 | 0.090 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2012 | 194 | 0.090 |
Why?
| | Conditioning, Operant | 1 | 2010 | 97 | 0.090 |
Why?
| | Extinction, Psychological | 1 | 2010 | 78 | 0.080 |
Why?
| | Vision, Ocular | 1 | 2009 | 30 | 0.080 |
Why?
| | Chickens | 2 | 2006 | 177 | 0.080 |
Why?
| | Light Signal Transduction | 1 | 2009 | 4 | 0.080 |
Why?
| | Amacrine Cells | 1 | 2009 | 14 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2019 | 3535 | 0.080 |
Why?
| | Cyclic AMP | 2 | 2006 | 227 | 0.080 |
Why?
| | Rats | 4 | 2010 | 4958 | 0.080 |
Why?
| | Male | 10 | 2020 | 55606 | 0.080 |
Why?
| | Cocaine | 1 | 2010 | 153 | 0.080 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 22 | 0.080 |
Why?
| | Cells, Cultured | 4 | 2014 | 3886 | 0.080 |
Why?
| | Receptors, Dopamine D4 | 1 | 2008 | 24 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2011 | 470 | 0.080 |
Why?
| | Visual Pathways | 1 | 2008 | 44 | 0.070 |
Why?
| | Retinal Diseases | 1 | 2008 | 76 | 0.070 |
Why?
| | Apoptosis | 3 | 2021 | 2363 | 0.070 |
Why?
| | United States | 2 | 2020 | 12186 | 0.070 |
Why?
| | Nerve Growth Factors | 1 | 2007 | 71 | 0.070 |
Why?
| | Retrospective Studies | 1 | 2023 | 12555 | 0.070 |
Why?
| | RNA, Messenger | 6 | 2012 | 2553 | 0.070 |
Why?
| | Mammals | 1 | 2008 | 244 | 0.070 |
Why?
| | Adenylyl Cyclases | 1 | 2006 | 83 | 0.070 |
Why?
| | Calmodulin | 1 | 2006 | 71 | 0.070 |
Why?
| | Middle Aged | 3 | 2021 | 26738 | 0.070 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2005 | 5 | 0.060 |
Why?
| | Imidazoles | 2 | 2021 | 208 | 0.060 |
Why?
| | Retinal Ganglion Cells | 1 | 2005 | 92 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 785 | 0.060 |
Why?
| | Early Growth Response Protein 1 | 1 | 2023 | 24 | 0.060 |
Why?
| | Phenotype | 2 | 2023 | 2796 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 94 | 0.050 |
Why?
| | Fibronectins | 1 | 2023 | 108 | 0.050 |
Why?
| | Oximes | 1 | 2021 | 19 | 0.050 |
Why?
| | Protein Binding | 1 | 2006 | 1890 | 0.050 |
Why?
| | Retinal Degeneration | 2 | 2012 | 30 | 0.050 |
Why?
| | Indazoles | 1 | 2021 | 58 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2003 | 923 | 0.040 |
Why?
| | Homovanillic Acid | 1 | 2000 | 7 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 316 | 0.040 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2021 | 81 | 0.040 |
Why?
| | Lighting | 1 | 2000 | 25 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 146 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 849 | 0.040 |
Why?
| | Neurons | 1 | 2007 | 1280 | 0.040 |
Why?
| | Validation Studies as Topic | 1 | 2019 | 23 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2000 | 368 | 0.040 |
Why?
| | Dasatinib | 1 | 2018 | 46 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 309 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 698 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 33 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.040 |
Why?
| | Oscillometry | 1 | 2018 | 33 | 0.040 |
Why?
| | Cell Survival | 2 | 2012 | 1021 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 130 | 0.030 |
Why?
| | Drug Interactions | 2 | 2010 | 338 | 0.030 |
Why?
| | Chick Embryo | 2 | 2006 | 122 | 0.030 |
Why?
| | Blotting, Western | 2 | 2011 | 1147 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 439 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2007 | 292 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 725 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2014 | 52 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4100 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 923 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2637 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 79 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 89 | 0.030 |
Why?
| | Body Weight | 1 | 2018 | 869 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9088 | 0.030 |
Why?
| | Mucoproteins | 1 | 2012 | 10 | 0.030 |
Why?
| | Opsins | 1 | 2012 | 10 | 0.030 |
Why?
| | Pineal Gland | 1 | 2012 | 13 | 0.030 |
Why?
| | Nerve Tissue Proteins | 2 | 2006 | 529 | 0.030 |
Why?
| | Bromodeoxyuridine | 1 | 2012 | 72 | 0.030 |
Why?
| | Oncogene Proteins | 1 | 2012 | 53 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2012 | 118 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2012 | 135 | 0.020 |
Why?
| | Eye Diseases, Hereditary | 1 | 2012 | 11 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2014 | 523 | 0.020 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2012 | 21 | 0.020 |
Why?
| | Transcription Factors | 2 | 2012 | 1528 | 0.020 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2012 | 34 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2012 | 239 | 0.020 |
Why?
| | Heterozygote | 1 | 2012 | 251 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 301 | 0.020 |
Why?
| | Pedigree | 1 | 2012 | 460 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2012 | 487 | 0.020 |
Why?
| | Thiones | 1 | 2010 | 14 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 122 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 367 | 0.020 |
Why?
| | Norepinephrine | 1 | 2010 | 201 | 0.020 |
Why?
| | Darkness | 1 | 2009 | 23 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1226 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2009 | 53 | 0.020 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2009 | 13 | 0.020 |
Why?
| | Transducin | 1 | 2009 | 40 | 0.020 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2009 | 14 | 0.020 |
Why?
| | Food | 1 | 2010 | 160 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 1828 | 0.020 |
Why?
| | CLOCK Proteins | 1 | 2008 | 8 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3003 | 0.020 |
Why?
| | Periodicity | 1 | 2008 | 55 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2009 | 164 | 0.020 |
Why?
| | Zebrafish | 1 | 2012 | 412 | 0.020 |
Why?
| | Sensory Deprivation | 1 | 2008 | 6 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2008 | 68 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2008 | 271 | 0.020 |
Why?
| | Proteoglycans | 1 | 2008 | 107 | 0.020 |
Why?
| | Calcium Channel Agonists | 1 | 2006 | 10 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 2968 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 7 | 0.020 |
Why?
| | ARNTL Transcription Factors | 1 | 2006 | 13 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 106 | 0.020 |
Why?
| | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2005 | 1 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 114 | 0.020 |
Why?
| | Photoperiod | 1 | 2006 | 48 | 0.020 |
Why?
| | Quinpirole | 1 | 2005 | 9 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2009 | 554 | 0.020 |
Why?
| | Cryptochromes | 1 | 2006 | 23 | 0.020 |
Why?
| | Kainic Acid | 1 | 2005 | 31 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2007 | 304 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2005 | 37 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2218 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2005 | 241 | 0.020 |
Why?
| | Receptors, Dopamine D2 | 1 | 2005 | 86 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2007 | 778 | 0.010 |
Why?
| | Calcium Signaling | 1 | 2006 | 217 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 6220 | 0.010 |
Why?
| | Physical Conditioning, Animal | 1 | 2006 | 194 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1842 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1421 | 0.010 |
Why?
| | Aged | 1 | 2019 | 19074 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1019 | 0.010 |
Why?
| | Aging | 1 | 2009 | 1618 | 0.010 |
Why?
| | Brain | 1 | 2010 | 2371 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 6116 | 0.010 |
Why?
|
|
Pozdeyev's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|